Connect with us
Prague Gaming & TECH Summit 2024

Artificial Intelligence

Ocular Drug Delivery Market Size to Outstrip $27,016.20Mn by 2028 Growth Projections at 7.4% CAGR During 2021 to 2028 COVID Impact and Global Analysis by TheInsightPartners.com

Published

on

New York, Oct. 05, 2021 (GLOBE NEWSWIRE) — Ocular Drug Delivery Market: Key Insights
According to our new research study on “Ocular Drug Delivery Market to 2028 – Global Analysis and Forecast – by Technology, Formulation Type, Disease Type, End User, and Geography,” the Ocular Drug Delivery Market Size is projected to reach US$ 27,016.20 million by 2028 from US$ 16,404.32 million in 2021; it is expected to grow at a CAGR of 7.4% from 2021 to 2028.

Ocular Drug Delivery Market: Competitive Landscape
AbbVie Inc.; Bausch Health Companies Inc.; Taiwan Liposome Company, Ltd.; Ocular Therapeutix, Inc., Graybug Vision, Inc.; Alimera Sciences, Inc.; Envisia Therapeutics; Novartis AG; EyeGate Pharmaceuticals, Inc; and Clearside Biomedical, Inc. are among the key companies operating in the ocular drug delivery market. The major market players are focusing on the launch of new products, expansion and diversification of market presence, and acquisition of new customer base, thereby tapping prevailing business opportunities.  

In March 2020, AbbVie (Allergan plc.) received FDA approval for DURYSTA (bimatoprost implant). It is the first and only intracameral biodegradable sustained-release implant to lower intraocular pressure in open-angle glaucoma or ocular hypertension patients.

In December 2020, EyeGate Pharmaceuticals, Inc. acquired Panoptes Pharma, a privately-held clinical-stage biotech company focused on developing a novel proprietary small molecule for the treatment of severe eye diseases.

Get Exclusive Sample Pages of Ocular Drug Delivery Market Size – COVID-19 Impact and Global Analysis with Strategic Insights at https://www.theinsightpartners.com/sample/TIPRE00004206/

North America to Dominate Ocular Drug Delivery Market:
The North America ocular drug delivery market is further segmented into the US, Canada, and Mexico. The US is the most significant contributor to the market in this region. The leading position of North America in the global ocular drug delivery market is primarily attributed to product awareness, an increase in the prevalence of eye diseases, and the presence of major market players in the region. Further, the aging population in the US is likely to increase the incidence of eye diseases, which will eventually drive the adoption of ocular drug delivery products in the country. For instance, as per the Population Reference Bureau 2019, the number of individuals in the US aged 65 and older is estimated to double from 52 million in 2018 to around 95 million by 2060, and the 65 and more age group’s share of the total population will increase from 16% to 23%. This aged population is highly vulnerable to eye conditions. For instance, as per the American Academy of Ophthalmology 2019 study, an estimated 7.32 million people aged 70–75 will be affected by primary open-angle glaucoma (POAG) by 2050 in the US.     

The Asia Pacific ocular drug delivery market is mainly represented by China, Japan, India, Australia, and South Korea. The rest of the countries in Asia Pacific also contribute to the regional market growth. The market in this region is driven by rising incidence of visual impairments, growing geriatric population in the region, and increasing number of pharmaceutical and biotech companies in this region. China is facing similar problems regarding eye diseases or disorders. In April 2018, the country reported that approximately 720 million people were affected by short-sightedness. The country also has the largest number of people with uncorrected poor vision, and it is expected the numbers are likely to boom in the coming future. Also, the country has a large number of ophthalmologists. There are approximately 28,000 ophthalmologists, which are five times more than the World Health Organization’s guidelines. Therefore, considering the factors mentioned above, the market for ocular drug delivery is expected to propel during the forecast period.

The leading cause of blindness or low vision across the globe is cataract, glaucoma, age-related macular degeneration, diabetic retinopathy, and unaddressed refractive error. The majority of the global population have or had some eye disorder in their lifetime. As per the World Health Organization (WHO) report “Blindness and vision impairment” published in February 2021, around 2.2 billion people worldwide have a near or distance vision impairment. It has also estimated that the leading cause of vision loss or low vision is cataract (94 million) and uncorrected refractive errors (88.4 million). Further, the other common causes of vision loss are glaucoma (7.7 million), corneal opacities (4.2 million), diabetic retinopathy (3.9 million), and trachoma (2 million).

Download Sample PDF Brochure of Ocular Drug Delivery Market Size and Growth Research Report at https://www.theinsightpartners.com/sample/TIPRE00004206/

According to the National Eye Institute (NEI), in the US, the number of people with cataracts is expected to double from 24.4 million in 2010 to about 50 million in 2050. Similarly, as per the Factsheet Glaucoma: Facts & Figures 2019, over 3 million people in the US were living with glaucoma.  Moreover, as per the Canadian Survey on Disabilities 2017, 1.5 million Canadians had a sight loss, and around 5.59 million had an eye disease which could further lead to sight loss.

Additionally, as per the Royal National Institute of Blind People in 2017, in the UK, there were around 350,000 people registered as blind and partially sighted; about 173,735 were registered for severely sight impaired; and 176,125 were registered for sight-impaired.    

Ocular Drug Delivery Market: Segmental Overview
Based on technology, the ocular drug delivery market is segmented into implantable ocular drug delivery systems, particulate drug delivery systems, nano-particle drug delivery system, and others. The implantable ocular drug delivery systems segment would account for the largest market share in 2021, and the same segment is anticipated to register the highest CAGR during the forecast period.

Based on formulation type, the ocular drug delivery market is segmented into liposomes and nanoparticles, solution, emulsion, suspension, and ointment. The solution segment would hold the largest share of the market in 2021, and it is estimated to register the highest CAGR in the market during 2021–2028. The growth of the solution segment is attributed to the increasing adoption of ocular drug delivery systems in solution forms, like eye drops and injectables.

Based on disease type, the ocular drug delivery market is segmented into glaucoma, diabetic retinopathy, dry eye syndrome, macular degeneration, cataract, diabetic macular edema, and others. The cataract segment would account for the largest market share in 2021. The market for this segment is estimated to grow at the highest CAGR from 2021 to 2028.

Order a Copy of Ocular Drug Delivery Market Size, Share, Strategic Insights and Forecasts 2021-2028 Research Report at https://www.theinsightpartners.com/buy/TIPRE00004206/

Based on end user, the ocular drug delivery market is segmented into hospitals, ophthalmic clinics, and ambulatory surgical centers. The hospitals segment would hold the largest share of the market in 2021, while the ophthalmic clinics segment is estimated to register the highest CAGR in the market during the forecast period. 

Impact of COVID-19 Pandemic on Ocular Drug Delivery Market:
The COVID-19 pandemic has become the most significant challenge across the world. As this pandemic has stressed healthcare systems across the globe, prioritizing the limited resources was essential to minimize hospital admissions. However, despite increased demand for ocular therapeutics such as eye drops, ointment, and suspension, there was a shortage of these products as new consumers entered the market. Manufacturers are also experiencing raised prices and potential shortages of raw ingredients due to supply restrictions. However, as the restrictions have been lifted and businesses are resuming, the demand-supply variables are coming back to normal. This will offer several growth prospects for ocular drug delivery therapeutics.   
   

Browse Related Reports:
Liposome Drug Delivery Market Forecast to 2027 – COVID-19 Impact and Global Analysis by Product (Liposomal Doxorubicin, Liposomal Paclitaxel, Liposomal Amphotericin B, Others); Technology ( Stealth Liposome Technology, Non-PEGylated Liposome Technology, DepoFoam Liposome Technology, Lysolipid Thermally Sensitive Liposome (LTSL)); Application (Fungal Diseases, Cancer Therapy, Pain Management, Viral Vaccines, Photodynamic Therapy)

Implantable Drug Delivery Devices Market Forecast to 2028 – COVID-19 Impact and Global Analysis By Product Type (Contraceptive Implants, Spinal Implants, Brachytherapy Seeds, Drug-Eluting Stents, Bio-absorbable Stents, Intraocular Stents, Infusion Pumps); Technology (Biodegradable Implants, Non-biodegradable Implants); Application (Ophthalmology, Oncology, Cardiovascular, Birth control, Opioid use disorder, Others)

Liposome Assisted Drug Delivery Market Forecast to 2028 – COVID-19 Impact and Global Analysis by Product (Liposomal Doxorubicin, Liposomal Amphoteracin B, Liposomal Paclitaxel, Others); Application (Fungal Infection Therapy, Cancer and Tumor Therapy, Others)

Subcutaneous Drug Delivery Market Forecast to 2028 – Covid-19 Impact and Global Analysis – By Product Type (Fillable Injectable, Prefilled Injectable) ; Type (Disposable subcutaneous drug delivery injectable, Reusable subcutaneous drug delivery injectable) ; Technology type (Jet, Spring, Gas) ; Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Drug store, Online Pharmacies)

Pulmonary Drug Delivery Devices/Systems Market Forecast to 2028 – COVID-19 Impact and Global Analysis By Product (Capsule Endoscopy, Drug Delivery, Patient Monitoring) By Application (Asthma, COPD, Allergic Rhinitis, Cystic Fibrosis and Others) and By End User (Hospitals & Clinics, Research Institutes and Home Healthcare)

Next Generation Diabetes Therapy And Drug Delivery Market Forecast to 2028 – Covid-19 Impact and Global Analysis – By Product Type (Inhalable Insulin, Oral Insulin, Insulin Patches, CGM Systems, Artificial Pancreas); Indication (Type 1 Diabetes, Type 2 Diabetes); End-User (Diagnostics/Clinics, ICUs, Home Healthcare) and Geography

Drug Delivery Systems Market to 2027- Global Analysis and Forecasts by Route of Administration (Oral, Transmucosal, Injectable, Topical, Implantable, and Ocular); Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies); Application (Hospitals & Clinics, Home Care Settings, and Others) and Geography

Pharmaceutical Drug Delivery Market Forecast to 2027 – COVID-19 Impact and Global Analysis by Route of Administration (Oral Drug Delivery, Injectable Drug Delivery, Topical Drug Delivery, Ocular Drug Delivery, Pulmonary Drug Delivery, Nasal Drug Delivery, Transmucosal Drug Delivery, Implantable Drug Delivery); Application (Infectious Diseases, Cancer, Cardiovascular Diseases, Diabetes, Respiratory. Diseases, Central Nervous System Disorders, Autoimmune Diseases, and Other Diseases); End User (Hospitals, Home Care Settings, ASC/Clinics, Other End Users), and Geography

Transmucosal Drug Delivery Systems Market Forecast to 2028 – Covid-19 Impact and Global Analysis – By Type (Passive Transdermal Drug Delivery, and Active Transdermal Drug Delivery); End User (Hospitals, Clinics and Others)

About Us:
The Insight Partners is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We specialize in industries such as Semiconductor and Electronics, Aerospace and Defense, Automotive and Transportation, Biotechnology, Healthcare IT, Manufacturing and Construction, Medical Device, Technology, Media and Telecommunications, Chemicals and Materials.

Contact Us:
If you have any queries about this report or if you would like further information, please contact us:

Contact Person: Sameer Joshi
E-mail: [email protected]
Phone: +1-646-491-9876
Press Release – https://www.theinsightpartners.com/pr/ocular-drug-delivery-market

Connect With Us on:
LinkedIn: https://www.linkedin.com/company/7591674/admin/
Twitter: https://twitter.com/tipmarkettrends
Facebook: https://www.facebook.com/theinsightpartners/
YouTube: https://www.youtube.com/c/TheInsightPartners
RSS/Feeds: https://www.theinsightpartners.com/feed/ | https://www.prnewswire.com/news/the-insight-partners/

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Artificial Intelligence

Automotive Digital Cockpit Domain Controller Power Expected to Double by 2030

Published

on

automotive-digital-cockpit-domain-controller-power-expected-to-double-by-2030

NEW YORK, March 28, 2024 /PRNewswire/ — The lengthening lifecycle of vehicles is driving automotive Original Equipment Manufacturers (OEMs) to plan several years of customer support through regular Over-the-Air (OTA) updates. Achieving this requires a digital Cockpit Domain Controller (CDC) with an architecture that supports long-term updating and maintenance. According to a new report from global technology intelligence firm ABI Research, the computing power of the CDC will increase significantly over the next few years, with graphical computing power and deep-learning processing power (for AI-powered functions) expected to double by 2030 for an average mid-market CDC.

OEMs are beginning to plan for several years of support, both in software patches and bug fixes, and for delivering new added value features to the driving experience. “This support and feature roadmap requires a hardware and software architecture that supports the continuous updating of vehicles over time. OEMs need a system that accommodates quick, targeted updates by shipping vehicles with planned overhead in computing power, software containerization, and robust hypervisors. These can be accommodated by silicon vendors such as NVIDIA or Qualcomm with their suite of high-powered System-on-Chips (SoCs), along with hypervisor and software specialists such as Blackberry QNX. The ecosystem hasn’t fully adjusted to OTA updates in mixed-criticality systems like the digital cockpit domain controller yet, with most OEMs speculating about the level of computing power that is needed for several years of support and few going to their silicon and tier-one partners with roadmaps of planned features,” explains Abu Miah, Smart Mobility and Automotive Analyst at ABI Research.
The computing power of the CDC will increase significantly over time. The Tera Floating-Point Operations per Second (TFLOPS) of an average mid-market CDC is expected to rise from 1 TFLOPS in 2023 to 2.5 TFLOPS by 2030. Miah adds, “One of the primary drivers of this increase is the implementation of a larger number of higher resolution screens in the vehicle to accommodate new high-end gaming and video-on-demand features.”
Building a ‘future-proofed’ CDC is not as simple as throwing compute power at the vehicle. “OEMs, tier ones, and silicon vendors must all work toward an ecosystem of hardware and software agnosticism, modular architecture, and collaborative software development if they are to match customers’ expectations of updates, patches, and bug fixes from the consumer electronics space,” Miah concludes.
These findings are from ABI Research’s Future-Proofing Digital Cockpit Domain Controllers application analysis report. This report is part of the company’s Smart Mobility and Automotive research service, which includes research, data, and ABI Insights. Based on extensive primary interviews, Application Analysis reports present an in-depth analysis of key market trends and factors for a specific technology.
About ABI Research
ABI Research is a global technology intelligence firm uniquely positioned at the intersection of technology solution providers and end-market companies. We serve as the bridge that seamlessly connects these two segments by providing exclusive research and expert guidance to drive successful technology implementations and deliver strategies proven to attract and retain customers.
ABI Research是一家全球性的技术情报公司,拥有得天独厚的优势,充当终端市场公司和技术解决方案提供商之间的桥梁,通过提供独家研究和专业性指导,推动成功的技术实施和提供经证明可吸引和留住客户的战略,无缝连接这两大主体。
For more information about ABI Research’s services, contact us at +1.516.624.2500 in the Americas, +44.203.326.0140 in Europe, +65.6592.0290 in Asia-Pacific, or visit www.abiresearch.com.
Contact Info: 
GlobalDeborah Petrara Tel: +1.516.624.2558 [email protected] 
Logo – https://mma.prnewswire.com/media/2309035/ABI_Research_2024.jpg

View original content:https://www.prnewswire.co.uk/news-releases/automotive-digital-cockpit-domain-controller-power-expected-to-double-by-2030-302101973.html

Continue Reading

Artificial Intelligence

ACL Digital in Collaboration with AWS and Infineon to Participate at Embedded World 2024

Published

on

acl-digital-in-collaboration-with-aws-and-infineon-to-participate-at-embedded-world-2024

SAN JOSE, Calif., March 28, 2024  /PRNewswire/ — ACL Digital, an ALTEN group company, is a pioneer in design-led digital experience, innovation, enterprise IT modernization, and product engineering services, announced that ACL Digital, in collaboration with AWS and Infineon, is going to showcase its AWS IoT & Cloud capabilities at Embedded World 2024, Hall 4 (Booth #4-552) from April 9 to April 11 in Nuremberg, Germany.

ACL Digital, a top-tier AWS Services partner, propels organizations of all sizes to navigate digital transformation to accelerate time-to-market. The company provides comprehensive support, from adopting to modernizing IT infrastructure on AWS. By leveraging expertise in architecture, security, migration, and operations, ACL Digital unlocks the full potential of AWS, streamlining IoT and cloud journeys and fast-tracking business growth and innovation.
The AWS Advanced Tier partnership enables ACL Digital to leverage AWS expertise, its robust support ecosystem and best practices to deliver customer delight.
ACL Digital offers visitors at Embedded World 2024 a chance to experience the exclusive demo of a Smart Stove Solution, built by leveraging the AWS Cloud and Infineon platform and how it has added value to our customers.
With over 100 AWS-certified experts, ACL Digital empowers clients to achieve breakthrough results in their digital transformation. Also, the leading digital transformation company supports global clients in navigating the complexities of cloud implementation, migration and digital transformation with ease and helping them unlock new growth opportunities.
About AWS
Since 2006, Amazon Web Services has been the world’s most comprehensive and broadly adopted cloud. AWS has been continually expanding its services to support virtually any workload, and it now has more than 240 fully featured services for compute, storage, databases, networking, analytics, machine learning and artificial intelligence (AI), Internet of Things (IoT), mobile, security, hybrid, media, and application development, deployment, and management from 105 Availability Zones within 33 geographic regions, with announced plans for 12 more Availability Zones and four more AWS Regions in Malaysia, New Zealand, Thailand, and the AWS European Sovereign Cloud. Millions of customers—including the fastest-growing startups, largest enterprises, and leading government agencies—trust AWS to power their infrastructure, become more agile, and lower costs. To learn more about AWS, visit https://aws.amazon.com .
About Infineon
Infineon Technologies AG is a global semiconductor leader in power systems and IoT. Infineon drives decarbonization and digitalization with its products and solutions. The company has around 58,600 employees worldwide and generated revenue of about €16.3 billion in the 2023 fiscal year (ending 30 September). Infineon is listed on the Frankfurt Stock Exchange (ticker symbol: IFX) and in the USA on the OTCQX International over-the-counter market (ticker symbol: IFNNY). To learn more about Infineon, visit https://www.infineon.com/
About ACL Digital
ACL Digital an ALTEN Group Company, is a digital product innovation and engineering leader. We help our clients design and build innovative products (AI, Cloud, and Mobile ready), content and commerce-driven platforms, and connected, converged digital experiences for the modern world through a design-led Digital Transformation framework.
Headquartered in Silicon Valley, ACL Digital is a leader in design-led digital experience, innovation, enterprise modernization, and product engineering services converging to Technology, Media & Telecom. The company has a workforce of 57,000+ spread across more than 30+ countries.

View original content:https://www.prnewswire.co.uk/news-releases/acl-digital-in-collaboration-with-aws-and-infineon-to-participate-at-embedded-world-2024-302101481.html

Continue Reading

Artificial Intelligence

Gilbarco Veeder-Root champions fuel efficiency, clean fuels and diesel rebate solutions in mining

Published

on

gilbarco-veeder-root-champions-fuel-efficiency,-clean-fuels-and-diesel-rebate-solutions-in-mining

JOHANNESBURG, March 28, 2024 /PRNewswire/ — Global leader in technology solutions OEM Gilbarco Veeder-Root (GVR) is dedicated to enhancing operational performance by delivering comprehensive end-to-end wetstock, industrial, mining, and business-to-business solutions, all tailored to meet the specific needs of the customer.

 
 
By encompassing every aspect of mining operations, GVR commercial and industrial Middle East and Africa director Westtar Kapito says, “the company is setting new benchmarks for fuel efficiency, safety and sustainability within the mining industry”.
As part of a holistic approach to mining excellence, Kapito explains that Gilbarco’s integrated fuel and fleet management technology solutions are designed to address the multifaceted challenges of the mining industry.
Some of these facets include wetstock control, equipment maintenance and management, fleet management and automation, compliance monitoring and environmental sustainability, as well as driving productivity and profitability through innovation.
In addition, the introduction of Gilbarco’s clean fuel solution exemplifies the company’s commitment to maintaining equipment integrity and performance.
This technology, GVR says, monitors in real-time the status of up to 16 “clean fuels” key performance matrices, thereby ensuring that dirty fuel is flagged and not transferred into mining equipment which would affect engines and injectors and thus lower productivity.
Gilbarco’s comprehensive site automation solutions empower mining companies with critical data analytic insights, facilitating efficient monitoring and management of fleet and fuel inventory. Gilbarco’s dataFLEX360 platform plays a pivotal role, offering near real-time reporting and analytics to drive informed decision-making and operational agility.
dataFLEX360 is a Web-based, cloud-hosted strategic operational insights platform. The system ensures accurate, reliable and relevant reporting of all fuel, fleet and asset transactions, and provides for proactive corrective measures to reduce complex reporting and gives a consolidated and comprehensive view across all sites and assets.
With reconciliations at its core, dataFLEX360 provides solution accuracy on operational data.
Integral to the company’s solutions is compliance with Global Industry Standards and environmental stewardship, from leak detection to vapour recovery and clean fuel technologies. Gilbarco’s products are designed to ensure compliance and minimise the carbon footprint of mining operations.
Additionally, through the company’s innovative telematics technology and the data generated, it can systematically and seamlessly generate South African Revenue Services- (SARS-) compliant fuel rebate reports for any selected tax period.  
GVR’s technology provides a full audit trail required for eligibility for SARS rebates, and its reporting platform simplifies logbook and data gathering required, enabling successful rebate claims and return on investment.
Photo – https://mma.prnewswire.com/media/2373644/Gilbarco_Veeder_Roots_MEA.jpg

View original content:https://www.prnewswire.co.uk/news-releases/gilbarco-veeder-root-champions-fuel-efficiency-clean-fuels-and-diesel-rebate-solutions-in-mining-302102415.html

Continue Reading

Trending